About Alebund
Alebund is a company based in Shanghai (China) founded in 2018 by Gavin Xia and Jin Tian. Alebund has raised $114.5 million across 3 funding rounds from investors including Verition Fund Management, 3H Health Investment and Morningside China. Alebund operates in a competitive market with competitors including Calliditas Therapeutics, Unicycive, Akebia Therapeutics, Aurinia Pharmaceuticals and Renalys, among others.
- Headquarter Shanghai, China
- Founders Gavin Xia, Jin Tian
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$114.5 M (USD)
in 3 rounds
-
Latest Funding Round
$54.5 M (USD), Series B
Sep 13, 2021
-
Investors
Verition Fund Management
& 13 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Alebund
Unlock access to complete
Unlock access to complete
Funding Insights of Alebund
Alebund has successfully raised a total of $114.5M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $54.5 million completed in September 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Alebund
Alebund has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Verition Fund Management, 3H Health Investment and Morningside China.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment in health innovation and therapies is facilitated.
|
Locked | Locked | Locked | |
|
Mid-market companies are targeted for investment by Loayal Valley Capital.
|
Locked | Locked | Locked | |
|
BioVenture is focused on early and growth-stage healthcare investments.
|
Locked | Locked | Locked |
Investor details for Alebund
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Alebund
Investment portfolio details for Alebund
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Alebund
Detailed financials for Alebund
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Alebund Comparisons
Peer comparison for Alebund
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Alebund
Alebund operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Calliditas Therapeutics, Unicycive, Akebia Therapeutics, Aurinia Pharmaceuticals and Renalys, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of small molecule based drug for inflammatory kidney disease
|
|
| Locked | Locked | Locked |
Small molecule therapies for kidney diseases are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for kidney disease treatment are developed by Akebia Therapeutics.
|
|
| Locked | Locked | Locked |
Therapeutics for autoimmune diseases are developed by Aurinia Pharmaceuticals.
|
|
| Locked | Locked | Locked |
Therapeutics for renal diseases are developed and launched by Renalys.
|
Detailed competitors of Alebund
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Alebund
Complete news archive for Alebund
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alebund
Alebund was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Alebund is headquartered in Shanghai, China.
Gavin Xia is the current CEO of Alebund. They have also founded this company.
Alebund is a funded company, having raised a total of $114.5M across 3 funding rounds to date.
Alebund was established in 2018 in Shanghai, China, within the biotechnology sector. Focus is placed on developing therapeutics for kidney-related conditions. Operations center on advancing lead candidates such as AP-301 for hyperphosphatemia treatment, AP-303 for diabetic kidney disease, and AP-304 for autosomal dominant polycystic kidney disease. Further pipeline includes AP-302 and AP-305, an antibody targeting the complement lectin pathway for IgA nephropathy.
Alebund's top competitors include Calliditas Therapeutics, Akebia Therapeutics and Gennova.
Alebund has 14 investors. Key investors include Verition Fund Management, 3H Health Investment, Morningside China, Loayal Valley Capital, and BioVenture.